Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.

Wednesday, June 19, 2024

Dr. Minal Barve

Click the above link to view the abstract and video; login is required to view the video.

Click to view ASCO 2024 Presentation for Trial 20-06